Pembrolizumab monotherapy has shown long-lasting antitumor activity in non-small-cell lung cancer (NSCLC) expressing advanced programmed death ligand 1 (PD-L1, [18]). This evidence concerns the gene CD274 and non-small cell lung carcinoma.